



Atara Biotherapeutics
 Investor Relations Department
 701 Gateway Blvd, Suite 200
 South San Francisco, CA 94080
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: ATRA

Last Trade:	15.10
Trade Time:	12:37 PM ET May 23, 2017
Change:	-0.10 ▼ (-0.658%)
Day Range	14.80 - 15.30
52-Week Range	12.45 - 25.73
Volume	40,945


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We launched Atara Biotherapeutics in August 2012 to help patients combat cancer, kidney disease and other illnesses. Our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. Our goal is to help patients such as Atara Ciechanover, our company's namesake, who suffered from cancer before passing away in 2012. We aim to empower patients to fight their illnesses with better treatment options.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 10, 2017*
[Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- May 10, 2017*
[Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team](#)
- May 4, 2017*
[Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights](#)
- Apr 21, 2017*
[Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® \(pembrolizumab\) in Combination with ATA129 in Nasopharyngeal Carcinoma \(NPC\)](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 9, 2017*
[Annual Report \(10-K\)](#)
- Apr 25, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*
[Quarterly Report \(10-Q\)](#)